

Medical Cannabis as a Substitute for Opioids Are we Building an Ark or a Tower?

References:

1. National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: Current state of evidence and recommendations for research. Washington, DC. National Academies Press, 2017.
2. Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 National Survey on Drug Use and Health. <https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHFFR2017/NSDUHFFR2017.pdf>. Accessed May 28, 2019.
3. More Dispensaries in Colorado than McDonald's & Starbucks, Combined. December 25, 2015. <https://www.coloradopotguide.com/colorado-marijuana-blog/2015/december/26/more-dispensaries-in-colorado-than-mcdonalds-starbucks-combined/>. Accessed May 28, 2019.
4. FDA Regulation of Cannabis and Cannabis-Derived Products: Questions and Answers. <https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-questions-and-answers>. Accessed May 29, 2019.
5. United States Drug Enforcement Administration (DEA) Drug Scheduling. <https://www.dea.gov/drug-scheduling> Accessed May 29, 2019.
6. State Medical Marijuana Laws. National Conference of State Legislatures (NCSL). <http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx#3>. Accessed June 10, 2019.
7. Philpot LM, Ebbert JO, Hurt RT. A survey of the attitudes, beliefs and knowledge about medical cannabis among primary care providers. *BMC Fam Pract.* 2019;22;20(1):17.
8. Evanoff AB, Quan T, Dufault C, Awad M, Bierut LJ. Physicians-in-training are not prepared to prescribe medical marijuana. *Drug Alcohol Depend* 2017;180:151–5.
9. Lambert DM (Ed.). *Cannabinoids in Nature and Medicine*. Wiley-VCH. 2009, p. 20. ISBN 978-3906390567.
10. Small, E (1975). "American law and the species problem in Cannabis: Science and semantics". *Bulletin on Narcotics.* 27 (3): 1–20. PMID 1041693.
11. Hillig, Karl W.; Mahlberg, Paul G. (2004). "A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae)". *American Journal of Botany.* 91 (6): 966–975. doi:10.3732/ajb.91.6.966. PMID 21653452.
12. Fishedick, Justin Thomas; Hazekamp, Arno; Erkelens, Tjalling; Choi, Young Hae; Verpoorte, Rob (2010). "Metabolic fingerprinting of Cannabis sativa L., cannabinoids and terpenoids for chemotaxonomic and drug standardization purposes". *Phytochemistry.* 71 (17–18): 2058–2073. doi:10.1016/j.phytochem.2010.10.001. PMID 21040939.
13. Small, E. "Morphological variation of achenes of Cannabis". *Canadian Journal of Botany.* 1975;53 (10): 978–87. doi:10.1139/b75-117.
14. J.E. Joy; S. J. Watson, Jr.; J.A. Benson, Jr (1999). *Marijuana and Medicine: Assessing The Science Base*. Washington D.C: National Academy of Sciences Press. ISBN 978-0-585-05800-9.
15. Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. *Pharmacotherapy* 2013;33:195–209.
16. Mandolino, Giuseppe; Bagatta, Manuela; Carboni, Andrea; Ranalli, Paolo; Meijer, Etienne de (2003). "Qualitative and Quantitative Aspects of the Inheritance of Chemical Phenotype in Cannabis". *Journal of Industrial Hemp.* 8 (2): 51–72. doi:10.1300/J237v08n02_04. ISSN 1537-7881.

17. Guindon J, Hohmann AG. The endocannabinoid system and pain. *CNS Neurol Disord Drug Targets*. 2009;8(6):403-421.
18. Di Marzo V. Endocannabinoid' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. *Biochim Biophys Acta*. 1998;1392(2-3):153-175.
19. Wang J, Ueda N. Biology of endocannabinoid synthesis system. *Prostaglandins Other Lipid Mediat*. 2009;89(3-4):112-119.
20. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. *Proc Natl Acad Sci USA*. 1990;87(5):1932-1936.
21. McPartland JM, Duncan M, Di Marzo V, et al. Are cannabidiol and Δ^9 -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. *Br J Pharmacol*. 2014;172:737-753.
22. Felder CC, Joyce KE, Briley EM, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. *Mol Pharmacol*. 1995;48(3):443-450.
23. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. *Pharmacol Ther*. 1997;74(2):129-180.
24. Glass M, Faull RLM, Dragunow M. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study on the fetal, neonatal and adult human brain. *Neuroscience* 1997;77:299-318.
25. Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur J Biochem* 1995;232:54-61.
26. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature* 1990; 346:561-4.
27. Marsicano G, Goodenough S, Monory K, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. *Science*. 2003;302(5642):84-88.
28. Ishac EJN, Jiang L, Lake KD, Varga K, Abood ME, Kumos G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. *Br J Pharmacol* 1996; 118:2023-8. Full Text
29. Panikashvili D, Shein NA, Mechoulam R, et al. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. *Neurobiol Dis*. 2006;22(2):257-264.
30. Rom S, Persidsky Y. Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. *J Neuroimmune Pharmacol*. 2013;8(3):608-620.
31. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. *Science*. 2005;310(5746):329-332.
32. Rieder SA, Chauhan A, Singh U, et al. Cannabinoid-induced apoptosis in immune cells as a pathway to immuno-suppression. *Immunobiology*. 2010;215(8):598-605.
33. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. *Biochem Biophys Res Commun*. 1995;215(1):89-97.
34. Vogel Z, Barg J, Levy R, Saya D, Heldman E, Mechoulam R. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. *J Neurochem* 1993;61:352-5. Full Text
35. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. *J Pharmacol Exp Ther* 1994; 270:219-27.
36. Kanai Y, Hara T, Imai A. Participation of the spinal TRPV1 receptors in formalin-evoked pain transduction: a study using a selective TRPV1 antagonist, iodo-resiniferatoxin. *J Pharm Pharmacol*. 2006;58(4):489-493.

37. Ikeda-Miyagawa Y, Kobayashi K, Yamanaka H, Okubo M, Wang S, Dai Y, et al. Peripherally increased artemin is a key regulator of TRPA1/V1 expression in primary afferent neurons. *Mol Pain*. 2015;11:8.
38. Malek N, Starowicz K. Dual-acting compounds targeting endocannabinoid and endovanilloid systems-a novel treatment option for chronic pain management. *Front Pharmacol*. 2016;7:257.
39. Mlost J, Kostrzewa M, Malek N, Starowicz K. Molecular understanding of the activation of CB1 and blockade of TRPV1 receptors: implications for novel treatment strategies in Osteoarthritis. *Int J Mol Sci*. 2018;19(2).
40. Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. *Proc Natl Acad Sci USA*. 2002;99(16):10819-24.
41. Seierstad M, Breitenbucher JG. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. *J Med Chem*. 2008;51(23):7327-743.
42. Aizpurua-Olaizola, Oier; Soydaner, Umut; Öztürk, Ekin; Schibano, Daniele; Simsir, Yilmaz; Navarro, Patricia; Etxebarria, Nestor; Usobiaga, Aresatz (2016). "Evolution of the cannabinoid and terpene content during the growth of cannabis sativa plants from different chemotypes". *Journal of Natural Products*. 79 (2): 324–331. doi:10.1021/acs.jnatprod.5b00949. PMID 26836472.
43. Russo EB, Marcu J. Cannabis pharmacology: the usual suspects and a few promising leads. *Adv Pharmacol* 2017;80:71–138.
44. Nadal X, Del Rio C, Casano S, Palomares B, Ferreira-Vera C, Navarrete C, et al. Tetrahydrocannabinolic acid is a potent PPARgamma agonist with neuroprotective activity. *Br J Pharmacol* 2017;174(23):4263–76.
45. Verhoeckx KC, Korthout HA, van Meeteren-Kreikamp AP, Ehlert KA, Wang M, van der Greef J, et al. Unheated Cannabis sativa extracts and its major compound THC acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. *Int Immunopharmacol* 2006;6:656–65.
46. Rock EM, Sticht MA, Parker LA. Effects of phytocannabinoids on nausea and vomiting. In: Pertwee RG, editor. *Handbook of cannabis*. Oxford, UK: Oxford University Press; 2014. p. 435–54.
47. Sulak D, Saneto R, Goldstein B. The current status of artisanal Cannabis for the treatment of epilepsy in the United States. *Epilepsy Behav* 2017;70:328–33.
48. Bolognini D, Rock EM, Cluny NL, Cascio MG, Limebeer CL, Duncan M, et al. Cannabidiolic acid prevents vomiting in *Suncus murinus* and nausea-induced behavior in rats by enhancing 5-HT1A receptor activation. *Br J Pharmacol* 2013;168:1456–70.
49. Rock EM, Limebeer CL, Petrie GN, Williams LA, Mechoulam R, Parker LA. Effect of prior foot shock stress and Delta9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats. *Psychopharmacology (Berl)* 2017;234:2207–17.
50. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. *Journal of the American Chemical Society* 1964;86: 1646–7.
51. Huestis MA. Human cannabinoid pharmacokinetics. *Chem Biodivers*. 2007;4(8):1770-1804.
52. Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. *J Clin Pharmacol* 2002;42:11S–19S.
53. Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. *Br J Pharmacol* 2015;172:4790–805.
54. Thomas A, Baillie GL, Phillips AM, et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. *Br J Pharmacol* 2007;150:613–23. Full Text

55. Morgan C. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. *Br J Psychiatry* 2010; 197:285–90. Full Text
56. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol* 2011;163:1344–64.
57. Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. *Transl Psychiatry* 2012;2:1–7.
58. CESAMET™ (nabilone).
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf. Accessed June 10, 2019
59. MARINOL® (dronabinol).
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf. Accessed June 10, 2019
60. EPIDIOLEX Full Prescribing Information.
https://www.epidiolex.com/sites/default/files/EPIDIOLEX_Full_Prescribing_Information.pdf. Accessed June 10, 2019
61. EPIDIOLEX (cannabidiol) oral solution.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf. Accessed June 10, 2019
62. Sativex® | GW Pharmaceuticals, plc. <https://www.gwpharm.com/healthcare-professionals/sativex#>. Accessed June 10, 2019
63. FDA Regulation of Cannabis and Cannabis-Derived Products: Questions and Answers.
<https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-questions-and-answers>. Accessed June 10, 2019
64. Iversen L, Chapman V. Cannabinoids: a real prospect for pain relief? *Curr Opin Pharmacol* 2002;2:50–5.
65. Dogrul A, Seyrek M, Yalcin B, Ulugol A. Involvement of descending serotonergic and noradrenergic pathways in CB1 receptor-mediated antinociception. *Prog Neuropsychopharmacol Biol Psychiatry* 2012;38:97–105.
66. Seyrek M, Kahraman S, Devenci MS, Yesilyurt O, Dogrul A. Systemic cannabinoids produce CB₁-mediated antinociception by activation of descending serotonergic pathways that act upon spinal 5-HT(7) and 5-HT(2A) receptors. *Eur J Pharmacol*. 2010 Dec 15;649(1-3):183-94.
67. Lee MC, Ploner M, Wiech K, et al. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. *Pain*. 2013 Jan;154(1):124-34. doi: 10.1016/j.pain.2012.09.017.
68. Welch SP. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. *J Pharmacol Exp Ther* 1993;265:633–40.
69. Pertwee RG, Howlett AC, Abood ME, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. *Pharmacol Rev* 2010; 62:588–631.
70. Hulsebosch CE. Special issue on microglia and chronic pain. *Exp Neurol* 2012;234:253–4.
71. Beltramo M. Cannabinoid type 2 receptor as a target for chronic pain. *Mini Rev Med Chem* 2009;9:11–25.
72. Beltramo M, Bernardini N, Bertorelli R, et al. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. *Eur J Neurosci* 2006;23:1530–8.
73. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. *Science* 2005;310:329–32.
74. Jhaveri MD, Elmes SJ, Richardson D, et al. Evidence for a novel functional role of cannabinoid CB(2) receptors in the thalamus of neuropathic rats. *Eur J Neurosci* 2008;27:1722–30.
75. Anand U, Otto WR, Sanchez-Herrera D, et al. Cannabinoid receptor CB2 localisation and agonist mediated inhibition of capsaicin responses in human sensory neurons. *Pain* 2008;138:667–80.

76. Jhaveri MD, Sagar DR, Elmes SJ, Kendall DA, Chapman V. Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain. *Mol Neurobiol* 2007;36:26–35.
77. Nackley AG, Zvonok AM, Makriyannis A, Hohmann AG. Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. *J Neurophysiol* 2004;92: 3562–74.
78. Quartilho A, Mata HP, Ibrahim MM, et al. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. *Anesthesiology* 2003;99:955–60.
79. Richardson D, Pearson RG, Kurian N, et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteo-arthritis and rheumatoid arthritis. *Arthritis Res Ther* 2008;10:R43.
80. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P. Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. *Neuroscience* 2005;132:1093–102.
81. Wotherspoon G, Fox A, McIntyre P, Colley S, Bevan S, Winter J. Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. *Neuroscience* 2005;135:235–45.
82. Allan GM, Finley CR, Ton J, Perry D, Ramji J, Crawford K, Lindblad AJ, Korownyk C, Kolber MR. Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms. *Can Fam Physician*. 2018 Feb;64(2):e78-e94.
83. Fitzcharles MA, Ste-Marie PA, Häuser W, Clauw DJ, Jamal S, Karsh J, et al. Efficacy, tolerability, and safety of cannabinoid treatments in the rheumatic diseases: a systematic review of randomized controlled trials. *Arthritis Care Res* 2016;68(5):681-8.
84. Walitt B, Klose P, Fitzcharles MA, Phillips T, Häuser W. Cannabinoids for fibromyalgia. *Cochrane Database Syst Rev* 2016;(7):CD011694.
85. Tateo S. State of the evidence: cannabinoids and cancer pain-a systematic review. *J Am Assoc Nurse Pract* 2017;29(2):94-103. Epub 2016 Nov 10.
86. Lobos Urbina D, Peña Duran J. Are cannabinoids effective for treatment of pain in patients with active cancer? *Medwave* 2016;16(Suppl 3):e6539.
87. Stevens AJ, Higgins MD. A systematic review of the analgesic efficacy of cannabinoid medications in the management of acute pain. *Acta Anaesth Scand* 2017;61(3):268- 80. Epub 2017 Jan 16.
88. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. *JAMA* 2015;313(24):2456-73. Errata in: *JAMA* 2016;315(14):1522, *JAMA* 2015;314(21):2308, *JAMA* 2015;314(5):520, *JAMA* 2015;314(8):837.
89. Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. *Cochrane Database of Systematic Reviews* 2018, Issue 3. Art. No.: CD012182. DOI: 10.1002/14651858.CD012182.pub2.
90. Allan GM, Ramji J, Perry D, et al. Simplified guideline for prescribing medical cannabinoids in primary care. *Canad Fam Phys*. 2018;64(2):111-1204.
91. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. *Eur J Intern Med*. 2018 Mar;49:12-19. doi: 10.1016/j.ejim.2018.01.004. Epub 2018 Jan 4.
92. Ware MA, Wang T, Shapiro S, Collet JP, team Cs. Cannabis for the management of pain: assessment of safety study (COMPASS). *J Pain* 2015;16:1233–42.
93. Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex((R))), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. *Eur J Neurol* 2011;18:1122–31.
94. Sellers EM, Schoedel K, Bartlett C, Romach M, Russo EB, Stott CG, et al. A multiple dose, randomized, double-blind, placebo-controlled, parallel-group QT/QTc study to evaluate the electrophysiologic effects of THC/CBD spray. *Clin Pharmacol Drug Dev* 2013;2:285–94.

95. Russo EB, Mathre ML, Byrne A, Velin R, Bach PJ, Sanchez-Ramos J, et al. Chronic cannabis use in the compassionate investigational new drug program: an examination of benefits and adverse effects of legal clinical cannabis. *J Cannabis Ther* 2002;2:3–57.
96. Wade DT, Makela PM, House H, Bateman C, Robson PJ. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. *Mult Scler* 2006;12:639–45.
97. Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex(R) (nabiximols). *Mult Scler* 2012;18:219–28.
98. [50] Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. *J Neurol* 2013;260:285–95.
99. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. *Proc Natl Acad Sci U S A* 1990;87:1932–6.
100. Favrat B, Menetrey A, Augsburg M, Rothuizen L, Appenzeller M, Buclin T, et al. Two cases of “cannabis acute psychosis” following the administration of oral cannabis. *BMC Psychiatry* 2005;5:17.
101. Hirvonen J, Goodwin RS, Li CT, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. *Mol Psychiatry*. 2012;17(6):642–649. doi:10.1038/mp.2011.82
102. Martin-Sanchez E, Furukawa TA, Taylor J, Martin JL. Systematic review and meta-analysis of cannabis treatment for chronic pain. *Pain Med* 2009;10(8):1353-68. Epub 2009 Sep 1.
103. Colorado Department of Public Health and Environment, Vital Statistics Program. Available at: www.colorado.gov/pacific/cdphe/vital-statistics-program. Accessed August 18, 2018.
104. Bahraini NH, Gutierrez PM, Harwood J, et al. Colorado Violent Death Reporting System. *Public Health Reports*. 2012;127(3):304–309.
105. Hasin D. US Adult illicit cannabis use, cannabis use disorder, and medical marijuana laws, 1991-1992 to 2012-2013. *JAMA Psychiatry*. 2017;74(6):579-588.
106. Goyal H, Awad HH, Ghali JK. Role of cannabis in cardiovascular disorders. *J Thorac Dis*. 2017 Jul; 9(7): 2079–2092.
107. Uhegwu N, Bashir A, Hussain M, Dababneh H, Misthal S, Cohen-Gadol A. Marijuana induced Reversible Cerebral Vasoconstriction Syndrome. *J Vasc Interv Neurol*. 2015 Feb;8(1):36-8.
108. Monte AA, Shelton SK, Mills E, Saben J, Hopkinson A, Sonn B, Devivo M, Chang T, Fox J2, Brevik C, Williamson K, Abbott D. Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study. *Ann Intern Med*. 2019 Mar 26. doi: 10.7326/M18-2809. [Epub ahead of print]
109. Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. *Anesthesiology* 2007;107:785–96.
110. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized crossover clinical trial. *Neuropsychopharmacology* 2009;34:672–80.
111. Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo controlled, crossover trial of cannabis cigarettes in neuropathic pain. *J Pain* 2008;9:506–21.
112. Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. *J Pain* 2013;14: 1236–48.
113. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis potency over the last 2 decades (1995-2014): Analysis of Current Data in the United States. *Biol Psychiatry*. 2016 Apr 1;79(7):613-9. doi: 10.1016/j.biopsych.2016.01.004. Epub 2016 Jan 19.

114. Chandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, ElSohly MA. New trends in cannabis potency in USA and Europe during the last decade (2008-2017). *Eur Arch Psychiatry Clin Neurosci*. 2019 Feb;269(1):5-15. doi: 10.1007/s00406-019-00983-5. Epub 2019 Jan 22.
115. Highly Potent Weed: What We Know About The Health Effects: Shots - Health News: NPR. <https://www.npr.org/sections/health-shots/2019/05/15/723656629/highly-potent-weed-has-swept-the-market-raising-concerns-about-health-risks> .Accessed June 5, 2019.
116. Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid dose and label accuracy in edible medical cannabis products. *JAMA*. 2015;313(24):2491-2493. doi:10.1001/jama.2015.6613
117. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. *JAMA*. 2017;318 (17):1708-1709. doi:10.1001/jama.2017.11909
118. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proc Natl Acad Sci U S A*. 2012;109(40):E2657-E2664. doi:10.1073/pnas.1206820109.
119. Jackson NJ, Isen JD, Khoddam R, et al. Impact of adolescent marijuana use on intelligence: Results from two longitudinal twin studies. *Proc Natl Acad Sci U S A*.2016;113(5):E500-E508. doi:10.1073/pnas.1516648113.
120. Volkow ND, Koob GF, Croyle RT, Bianchi DW, Gordon JA, Koroshetz WJ, Pérez-Stable EJ, Riley WT, Bloch MH, Conway K, Deeds BG, Dowling GJ, Grant S, Howlett KD, Matochik JA, Morgan GD, Murray MM, Noronha A, Spong CY, Wargo EM, Warren KR, Weiss SRB. The conception of the ABCD study: From substance use to a broad NIH collaboration. *Dev Cogn Neurosci*. 2018 Aug;32:4-7. doi: 10.1016/j.dcn.2017.10.002. Epub 2017 Oct 10.
121. Arria AM, Caldeira KM, Bugbee BA, Vincent KB, O'Grady KE. The academic consequences of marijuana use during college. *Psychol Addict Behav*. 2015 Sep;29(3):564-75. doi: 10.1037/adb0000108. Epub 2015 Aug 3.
122. Marie O, Zölitz U. 'High' Achievers? Cannabis Access and Academic Performance. Discussion Paper No. 8900. IZA 2015. Forschungsinstitut zur Zukunft der Arbeit, Institute for the Study of Labor. Maastricht University.. <http://ftp.iza.org/dp8900.pdf>. Published in *The Review of Economic Studies* 2017 <http://www.restud.com/wp-content/uploads/2017/03/MS20610manuscript.pdf>. Accessed June 7, 2019
123. Gobbi G, Atkin T, Zytynski T, Wang Z, Askari S, Boruff J, Ware M, Marmorstein N, Cipriani A, Dendukuri N2, Mayo N. Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis. *JAMA Psychiatry*. 2019 Feb 13. doi: 10.1001/jamapsychiatry.2018.4500. [Epub ahead of print]
124. Gruber, S. A., & Sagar, K. A. (2017). Marijuana on the Mind? The Impact of Marijuana on Cognition, Brain Structure, and Brain Function, and Related Public Policy Implications. *Policy Insights from the Behavioral and Brain Sciences*, 4(1), 104–111.
125. Muller-Vahl KR, Emrich HM. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. *Expert Rev Neurother* 2008;8:1037–48.
126. Robson PJ, Guy GW, Di Marzo V. Cannabinoids and schizophrenia: therapeutic prospects. *Curr Pharm Des* 2014;20:2194–204.
127. Young-Wolff KC, Tucker L-Y, Alexeeff S, et al. Trends in Self-reported and Biochemically Tested Marijuana Use Among Pregnant Females in California From 2009-2016. *JAMA*. 2017;318(24):2490. doi:10.1001/jama.2017.17225
128. Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. *Neurotoxicol Teratol*. 2000;22(3):325-336.

129. Richardson GA, Ryan C, Willford J, Day NL, Goldschmidt L. Prenatal alcohol and marijuana exposure: effects on neuropsychological outcomes at 10 years. *Neurotoxicol Teratol.* 2002;24(3):309-320.
130. Perez-Reyes M, Wall ME. Presence of delta9-tetrahydrocannabinol in human milk. *N Engl J Med.* 1982;307(13):819-820. doi:10.1056/NEJM198209233071311.
131. Robledo , Berrendero F, Ozaita A, Maldonado R. Advances in the field of cannabinoid--opioid cross-talk. *Addict Biol.* 2008 Jun;13(2):213-24. doi: 10.1111/j.1369-1600.2008.00107.x.
132. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. *Life Sci* 2004;74:1317–24.
133. Ibrahim MM, Porreca F, Lai J, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. *Proc Natl Acad Sci U S A* 2005;102:3093–8.
134. Bushlin I, Rozenfeld R, Devi LA. Cannabinoid-opioid interactions during neuropathic pain and analgesia. *Curr Opin Pharmacol* 2010;10:80–6.
135. Cichewicz DL, McCarthy EA. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. *J Pharmacol Exp Ther* 2003;304:1010–15.
136. Zutler M, Holty JC. Opioids, sleep and sleep-disordered breathing. *Curr Pharm Des* 2011;17:1443–9.
137. Carley DW, Pavlovic S, Janelidze M, Radulovacki M. Functional role of cannabinoids in respiratory stability during sleep. *Sleep* 2002;25:388–95.
138. Reiman A, Welty M, Solomon P. Cannabis as a Substitute for Opioid-Based Pain Medication: Patient Self-Report. *Cannabis and Cannabinoid Research.* 2017; 2(1).
139. Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. *Int J Drug Policy.* 2017 Apr;42:30-35. doi: 10.1016/j.drugpo.2017.01.011. Epub 2017 Feb 9. PMID: 28189912
140. Olfson, M, Wall MM, Liu S, Blanco C. Cannabis use and risk of prescription opioid use disorder in the United States. *Am J Psychiatry* 2018; 175:47–53; doi: 10.1176/appi.ajp.2017.17040413
141. Campbell G, Hall WD, Peacock A, Lintzeris N, et al. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. *Lancet Public Health.* 2018 Jul;3(7):e341-e350. doi: 10.1016/S2468-2667(18)30110-5.
142. Bradford AC, Bradford WD. Medical marijuana laws reduce prescription medication use in Medicare part D. *Health Aff (Millwood)* 2016;35:1230–6.
143. Bradford AC, Bradford WD. Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. *Health Aff (Millwood)* 2017;36:945–51.
144. Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. *JAMA Intern Med* 2014;174:1668–73.
145. Shover CL, Davis CS, Gordon SC, Humphreys K. Association between medical cannabis laws and opioid overdose mortality has reversed over time. *Proceedings of the National Academy of Sciences* Jun 2019, 201903434; DOI: 10.1073/pnas.1903434116
146. Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. *J Pain Symptom Manage* 2013;46:207–18.
147. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. *Clin Pharmacol Ther* 2011;90:844–51.
148. Portenoy RK, Ganæ-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, McQuade R, Wright S, Fallon MT. Nabiximols for opioid-treated cancer patients with poorly-

controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. *J Pain*. 2012 May;13(5):438-49. doi: 10.1016/j.jpain.2012.01.003. Epub 2012 Apr 5.